Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn’s disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contact

Table 1 Patients’ clinical features at enrollment

Patient code	Age/Sex	Disease duration, years	Disease localization	CDAI	Therapy
#1	58 years/M	5	Ileo-colonic	170	MESA
#2	27 years/F	2	Ileal	293	MESA, AZA
#3	49 years/F	11	Colonic	253	MESA, AZA
#4	33 years/F	0	Colonic	255	AB, MESA
#5	78 years/M	33	Ileo-colonic	198	MESA
#6	48 years/F	0	Ileo-colonic	274	AB, MESA, PRED
#7	28 years/F	13	Ileo-colonic	426	MESA, BIO
#8	56 years/M	0	Colonic	313	BIO
#9	36 years/F	0,5	Colonic	288	MESA, AZA, PRED
#10	45 years/F	1	Ileo-colonic	301	MESA, AB
#11	49 years/M	0	Colonic	350	BIO-AZA
#12	28 years/F	10	Ileo-colonic	80	MESA
#13	32 years/M	7	Ileo-colonic	320	PRED - MESA
#14	62 years/F	17	Ileo-colonic	274	BIO, AZA
#15	47 years/M	11	Ileo-colonic	216	AZA, AB
#16	28 years/M	3	Ileo-colonic	368	BIO, AZA

CDAI Crohn’s disease activity index, M male, MESA mesalamine, F female, AZA azathioprine, AB antibiotics, PRED prednisone, BIO biologic (Infliximab)

ISSN: 1757-6512